Phase I‐II clinical trial of californium‐252. Treatment of stage IB carcinoma of the cervix

Yosh Maruyama; John R. Vannagell; Justine Yoneda; Elvis Donaldson; Holly Gallion; Ken Rowley; Richard Kryscio; Joseph L. Beach

doi:10.1002/1097-0142(19870415)59:8<1500::AID-CNCR2820590818>3.0.CO;2-9

Phase I‐II clinical trial of californium‐252. Treatment of stage IB carcinoma of the cervix

Yosh Maruyama, John R. Vannagell, Justine Yoneda, Elvis Donaldson, Holly Gallion, Ken Rowley, Richard Kryscio, Joseph L. Beach

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Intracavitary Californium‐252 combined with whole‐pelvis photon radiotherapy was tested as the sole form of treatment for 22 patients with Stage IB carcinoma of the cervix. Californium‐252 (Cf) is a fast neutron‐emitting radioisotope currently being tested in trials of neutron brachytherapy (NT). The outcomes of the treated group of patients were traced for local tumor control, survival, patterns of failure, and complications. The Cf intracavitary therapy combined with whole‐pelvis photon radiotherapy resulted in 95% 2‐year and 91% 5‐year actuarial survival. There were 9% Grade II‐III complications by the Stockholm scale and 4% local failures. These results were obtained in an early clinical trial with a group of largely poor‐risk patients with tumors of mean diameter of 4.3 cm.

Original language	English
Pages (from-to)	1500-1505
Number of pages	6
Journal	Cancer
Volume	59
Issue number	8
DOIs	https://doi.org/10.1002/1097-0142(19870415)59:8<1500::AID-CNCR2820590818>3.0.CO;2-9
State	Published - Apr 15 1987

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/1097-0142(19870415)59:8<1500::AID-CNCR2820590818>3.0.CO;2-9

Cite this

@article{438b3310711f4dbfb9bf7408c59c2308,

title = "Phase I‐II clinical trial of californium‐252. Treatment of stage IB carcinoma of the cervix",

abstract = "Intracavitary Californium‐252 combined with whole‐pelvis photon radiotherapy was tested as the sole form of treatment for 22 patients with Stage IB carcinoma of the cervix. Californium‐252 (Cf) is a fast neutron‐emitting radioisotope currently being tested in trials of neutron brachytherapy (NT). The outcomes of the treated group of patients were traced for local tumor control, survival, patterns of failure, and complications. The Cf intracavitary therapy combined with whole‐pelvis photon radiotherapy resulted in 95% 2‐year and 91% 5‐year actuarial survival. There were 9% Grade II‐III complications by the Stockholm scale and 4% local failures. These results were obtained in an early clinical trial with a group of largely poor‐risk patients with tumors of mean diameter of 4.3 cm.",

author = "Yosh Maruyama and Vannagell, {John R.} and Justine Yoneda and Elvis Donaldson and Holly Gallion and Ken Rowley and Richard Kryscio and Beach, {Joseph L.}",

year = "1987",

month = apr,

day = "15",

doi = "10.1002/1097-0142(19870415)59:8<1500::AID-CNCR2820590818>3.0.CO;2-9",

language = "English",

volume = "59",

pages = "1500--1505",

number = "8",

}

TY - JOUR

T1 - Phase I‐II clinical trial of californium‐252. Treatment of stage IB carcinoma of the cervix

AU - Maruyama, Yosh

AU - Vannagell, John R.

AU - Yoneda, Justine

AU - Donaldson, Elvis

AU - Gallion, Holly

AU - Rowley, Ken

AU - Kryscio, Richard

AU - Beach, Joseph L.

PY - 1987/4/15

Y1 - 1987/4/15

N2 - Intracavitary Californium‐252 combined with whole‐pelvis photon radiotherapy was tested as the sole form of treatment for 22 patients with Stage IB carcinoma of the cervix. Californium‐252 (Cf) is a fast neutron‐emitting radioisotope currently being tested in trials of neutron brachytherapy (NT). The outcomes of the treated group of patients were traced for local tumor control, survival, patterns of failure, and complications. The Cf intracavitary therapy combined with whole‐pelvis photon radiotherapy resulted in 95% 2‐year and 91% 5‐year actuarial survival. There were 9% Grade II‐III complications by the Stockholm scale and 4% local failures. These results were obtained in an early clinical trial with a group of largely poor‐risk patients with tumors of mean diameter of 4.3 cm.

AB - Intracavitary Californium‐252 combined with whole‐pelvis photon radiotherapy was tested as the sole form of treatment for 22 patients with Stage IB carcinoma of the cervix. Californium‐252 (Cf) is a fast neutron‐emitting radioisotope currently being tested in trials of neutron brachytherapy (NT). The outcomes of the treated group of patients were traced for local tumor control, survival, patterns of failure, and complications. The Cf intracavitary therapy combined with whole‐pelvis photon radiotherapy resulted in 95% 2‐year and 91% 5‐year actuarial survival. There were 9% Grade II‐III complications by the Stockholm scale and 4% local failures. These results were obtained in an early clinical trial with a group of largely poor‐risk patients with tumors of mean diameter of 4.3 cm.

UR - http://www.scopus.com/inward/record.url?scp=0023129975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023129975&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19870415)59:8<1500::AID-CNCR2820590818>3.0.CO;2-9

DO - 10.1002/1097-0142(19870415)59:8<1500::AID-CNCR2820590818>3.0.CO;2-9

M3 - Article

C2 - 3028603

AN - SCOPUS:0023129975

SN - 0008-543X

VL - 59

SP - 1500

EP - 1505

JO - Cancer

JF - Cancer

IS - 8

ER -

Phase I‐II clinical trial of californium‐252. Treatment of stage IB carcinoma of the cervix

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this